Despite "very interesting" preclinical data emerging on a heap of immuno-oncology molecules, "you still have to go into patients and show that it works," said Briggs Morrison, CEO of Syndax Pharmaceuticals Inc. "We went after patients with the biggest unmet need who are very hard to treat to try to demonstrate that we're actually seeing something in those patients. Not everybody has done that."